{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"62","upperLimit":"76","value":"69.5"},{"groupId":"OG001","lowerLimit":"64","upperLimit":"78","value":"71.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"224"}],"units":"Participants"}],"description":"Estimate for probability of progression free at 3 years by Kaplan-Meier method, where progression-free survival is defined as the time from randomization to the date of first documented disease recurrence/progression, death from any cause or date of last contact, whichever occurs first. Recurrence is defined as clinical, radiological or histological evidence of recurrent disease post study treatment. Disease progression will be determined from the physical examinations, which were conducted during treatment (day 9, 16, 23, 30 and 37) and follow-up (1 and 3 months after completing protocol therapy, every 3 months for years 1 and 2, and every 6 months for years 3, 4 and 5), and the PET/CT scan conducted 3 months after the end of treatment. Please note that progression defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST 1.1) is not required by the protocol.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive cisplatin IV over 90 minutes on days 2, 9, 16, 23, 30, (and day 36 or 37 at the treating physician's discretion). Patients then undergo EBRT (either conventional RT or IMRT) QD 5 days a week for 25 fractions followed by LDR or HDR brachytherapy according to institution's standards. Treatment continues in the absence of disease progression or unacceptable toxicity.\n\nBrachytherapy: Undergo brachytherapy\n\nCisplatin: Given IV\n\nExternal Beam Radiation Therapy: Undergo EBRT\n\nIntensity-Modulated Radiation Therapy: Undergo IMRT\n\nLaboratory Biomarker Analysis: Correlative studies\n\nRadiation Therapy: Undergo conventional RT","id":"OG000","title":"Arm I (Cisplatin, IMRT or RT, Brachytherapy)"},{"description":"Patients receive cisplatin and undergo EBRT followed by brachytherapy as in Arm I. Patients also receive triapine IV over 2 hours on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33. Treatment continues in the absence of disease progression or unacceptable toxicity.\n\nBrachytherapy: Undergo brachytherapy\n\nCisplatin: Given IV\n\nIntensity-Modulated Radiation Therapy: Undergo IMRT\n\nLaboratory Biomarker Analysis: Correlative studies\n\nRadiation Therapy: Undergo conventional RT\n\nTriapine: Given IV","id":"OG001","title":"Arm II (Cisplatin, IMRT or RT, Brachytherapy, Triapine)"}],"paramType":"NUMBER","populationDescription":"Eligible participants","reportingStatus":"POSTED","timeFrame":"At 3 years from study randomization.","title":"Progression-free Survival (PFS) Rate at 3 Years","type":"SECONDARY","unitOfMeasure":"percentage of participants"}